New facility for Kaneka

0

The board of the CDMO company Kaneka Eurogentec approved the construction of a new state of-the-art GMP facility adjacent to its current facility. The multi-product facility will include the capability for large scale biopharmaceuticals production using innovative Eurogentec technologies such as the improved production of complex proteins by secretion from yeasts and the production of kilo-scale plasmid DNA for viral and non-viral gene and cell therapies. Construction is expected to start in autumn of 2017. The state-of-the-art facility will be equipped for the production and purification of new biomedicines using cost-effective and safe microbial strains and will include the installation of a 2,200 L fermenter, harvest and purification equipment for all expression strategies.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here